The Colombian Association of Integral Medicine Companies (Acemi) warned that liquidating intervened EPS, as proposed by President Gustavo Petro, would risk care for millions by transferring them to entities like Nueva EPS, which lack capacity. The guild criticized deterioration during interventions and called for sensibility.
The Colombian Association of Integral Medicine Companies, Acemi, warned that President Gustavo Petro's proposal to liquidate intervened EPS would worsen Colombia's health system crisis. According to the guild, this would transfer affiliates to entities like Nueva EPS, which lack the financial and operational capacity to absorb a massive influx of users. Acemi noted that the Administrative Court of Antioquia provisionally suspended a territorial redistribution of affiliates between EPS, highlighting limitations in receiving entities. The eight EPS intervened by the National Superintendence of Health during this government show, per Acemi, greater patrimonial and operational deterioration, attributed to intervention management and non-compliance with Constitutional Court orders on financing. The guild stated interventions aimed to rescue entities and protect users but failed to solve issues. Separately, the Attorney General's Office determined that minor Kevin Arley Acosta Pico, with hemophilia, died on February 13 due to Nueva EPS omission in timely supplying Emicizumab for two months. Medicarte suspended deliveries due to non-payment, and IPS Integral received no funds. Another 2,000 patients are at risk. The Attorney General's Office will refer the case to the Attorney General's Office and open a disciplinary probe against Óscar Galvis, Nueva EPS intervener. Acemi called for “sensibility” and technical dialogue to stabilize the system for the next government.
